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To address the public health problem of antimicrobial
resistance, the European Union founded the European
Antimicrobial Resistance Surveillance System. A network
of 32 Spanish hospitals, serving ≈9.6 million persons, sub-
mitted antimicrobial-susceptibility data on 7,098 invasive
Escherichia coli species (2001–2003). Resistance to
ampicillin, cotrimoxazole, ciprofloxacin, gentamicin,
and tobramycin was found at rates of 59.9%, 32.6%,
19.3%, 6.8%, and 5.3%, respectively. Resistance to multi-
ple drugs increased from 13.8% in 2001 to 20.6% in 2003
(p < 0.0001). Antimicrobial consumption data were
obtained from the Spanish National Health System. In spite
of decreased cephalosporin and β-lactam use, overall
extended-spectrum β-lactamase production increased from
1.6% (2001) to 4.1% (2003) (p < 0.0001), mainly due to the
rising prevalence of cefotaximases. Resistance to
ciprofloxacin significantly increased, mostly in community-
onset infections, which coincided with a rise in community
quinolone use. Cotrimoxazole resistance remained stable
at ≈30%, even though its use was dramatically reduced. 
A
ntimicrobial resistance is a well-known clinical and
public health problem (1). For example, in the United
States in 2002, resistance to ampicillin and ciprofloxacin
among 5,192 Escherichia coli blood isolates was 47.8%
and 13.3%, respectively (2). The World Health
Organization (WHO), the European Commission, and the
U.S. Centers for Disease Control and Prevention (CDC)
have recognized the importance of studying the emergence
and determinants of resistance as well as the need for con-
trol strategies (1,3,4). 
The European Antimicrobial Resistance Surveillance
System (EARSS) is an international network of national
surveillance systems that attempts to collect reliable and
comparable antimicrobial resistance data of invasive
pathogens. The International Network for the Study and
Prevention of Emerging Antimicrobial Resistance has
similar goals (3). The purpose of EARSS is to document
variations in antimicrobial resistance over time and space
to provide the basis for developing prevention programs,
making policy decisions, and assessing the effectiveness
of both.
E. coli is one of the main causes of both nosocomial and
community-acquired infections in humans (5) and one of
the microorganisms most frequently isolated from blood
(2,6–8). Pathogenic isolates of E. coli have a relatively
large potential for developing resistance (2,5,7,9). In
recent years, fluoroquinolone resistance has increased in
some countries (2,10,11), CTX-M-type extended-spectrum
β-lactamase (ESBL) dissemination has been described
(12,13), and reports of multidrug resistance are not infre-
quent (9,14,15).
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del Medicamento; and ‡Hospital Ramón y Cajal, Madrid, SpainAmong western countries, Spain has one of the highest
rates of antimicrobial consumption (16,17) and antimicro-
bial resistance (15). The goal of this prospective study was
to describe and analyze the evolution of antimicrobial
resistance in comparison to antimicrobial use. Using 7,098
blood or cerebrospinal fluid (CSF) isolates of E. coli col-
lected by Spanish hospitals participating in the EARSS
network from 2001 to 2003, we found that antimicrobial
resistance, particularly to fluoroquinolones and third-gen-
eration cephalosporins, was increasing in E. coli.
Materials and Methods
Selection of Participating Hospitals 
To fulfill the goal of obtaining representative data, par-
ticipating hospitals were chosen to meet the following cri-
teria: 1) coverage of at least 20% of the Spanish
population, 2) different areas of the country covered, and
3) different kinds of hospitals (size and category) repre-
sented. The official catalog of all available Spanish hospi-
tals, as published by Spanish Ministry of Health, was used
to randomly select hospitals involved in this surveillance
system; 3 hospitals refused to participate and were
replaced by 3 other hospitals of similar characteristics.
Strains Studied 
All clinical isolates of E. coli obtained from blood and
CSF samples in microbiology laboratories of Spanish hos-
pitals that participated in EARSS from 2001 to 2003 were
included. Only the first invasive isolate per patient was
reported. Invasive infection was defined as infection with
an E. coli isolate from blood or CSF. Nosocomial infec-
tions were defined as infections acquired at least 48 h after
hospital admission. Patients with community-acquired
infections were those who had positive cultures by E. coli
at the time of or within 48 hof hospitalization.
Data Collection 
A questionnaire concerning hospital characteristics
(coverage, hospital type, number of beds, number of
patients admitted per year, hospital departments), methods
of antimicrobial susceptibility study, and interpretation cri-
teria was completed by each participating center. One iso-
late record form was completed for each patient. This form
included personal patient data (code, age, sex), hospital and
departmental data, and antimicrobial susceptibility data.
Participating hospitals sent prospectively standardized
results to the Ministry of Health, where results were ana-
lyzed and validated by using the laboratory-based
WHONET 5 program (WHO Collaborating Center for the
Surveillance of Antibiotic Resistance). Amedical microbi-
ologist carefully reviewed all records. 
Only the first isolate per patient and year was included.
Discrepancies and atypical results were resolved by tele-
phone inquiry, and the corresponding database records
were updated if necessary. At the end of each year, an
annual report of all data stored in the central database was
sent to each participating laboratory to avoid possible dis-
crepancies. 
Antimicrobial Susceptibility Studies 
The protocol for E. coli susceptibility testing included
the following antimicrobial agents: ampicillin, aminogly-
cosides (gentamicin and tobramycin), fluoroquinolones
(ciprofloxacin), and third-generation cephalosporins (cefo-
taxime and ceftazidime). Data on antimicrobial suscepti-
bility to additional antimicrobial agents were also
considered when this information was available for at least
5,900 isolates. For this reason, the number of strains stud-
ied for each antimicrobial agent in some cases was not the
same as the total number of strains. 
Each laboratory identified strains and tested their sus-
ceptibility according to standard microbiologic procedures.
In 29 laboratories, identification and antimicrobial suscep-
tibility tests were performed by using the following com-
mercial microdilution systems: 14 used MicroScan
(Dade-Behring, Deerfield, Illinois, USA); 8, Wider (Fco.
Soria Melguizo S.A., Madrid, Spain); 5, Vitek
(bioMérieux, Marcy l’Etoile, France); and 2, Sensititre
(Radiometer/ Copenhagen Company, Denmark). The 3
remaining laboratories used the disc-plate diffusion
method combined with E test strips (AB-Biodisk, Solna,
Sweden). Results were scored as susceptible, intermediate,
or resistant according to criteria established by the National
Committee for Clinical Laboratory Standards (NCCLS,
now the Clinical and Laboratory Standards Institute) (18).
Based on NCCLS criteria, a consensus guideline for
detecting ESBL production was recommended by EARSS
to all participants (18). ESBL producers were considered
resistant to both cefotaxime and ceftazidime independent
of their MIC in accordance with NCCLS criteria (18).
Multidrug resistance was defined as resistance to >3 of the
antimicrobial agents tested.
Quality Control 
To assess the comparability of susceptibility test
results, a quality assurance exercise was performed yearly
among the 32 participating laboratories. The U.K. National
External Quality Assessment Scheme designed the quality
controls. Altogether, 24 well-characterized control inva-
sive strains, including 6 E. coli strains with different resist-
ance phenotypes, were tested. All these external quality
control strains were recommended to be included in the
regular internal quality control procedures performed by
each laboratory. Data on susceptibility to ampicillin,
ciprofloxacin, gentamicin, cefotaxime, and ceftazidime
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questionnaire concerning the methods used for determin-
ing susceptibility and applying interpretation criteria.
Community Antimicrobial Use 
The Ministry of Health and Consumer Affairs main-
tains a drug database of retail pharmacy sales of all medi-
cines acquired with National Health System prescriptions,
covering nearly 100% of the Spanish population (17,19).
These data reflect the outpatient antimicrobial use in
Spain. This database was used to gather information on
sales for the period 1998–2003. The information was tab-
ulated, and the number of units sold was converted into
defined daily doses (DDD) of the active drug ingredients
in accordance with WHO guidelines (20). We then calcu-
lated the number of DDD per 1,000 inhabitants per day for
each of the active drug ingredients. This information was
not available in relation to patient age.
Statistical Analyses 
Differences in the prevalence of antimicrobial resist-
ance between different groups were assessed by Fisher
exact test. Association was determined by calculation of
the odds ratio (OR) with 95% confidence intervals (CI).
The null hypothesis was rejected for values of p < 0.05.
Statistical analyses were performed with EpiInfo version
6.04 software (CDC, Atlanta, GA, USA).
Results
Characteristics of Participating Laboratories 
From 2001 to 2003, a total of 32 laboratories reported
data on invasive E. coli isolates. The estimated average
coverage of the Spanish population was 23%, which corre-
sponds to ≈9.5 million persons. The median annual num-
bers of hospital beds and patients admitted were ≈14,500
and 550,000, respectively. Four hospitals (12.5%) had
>1,000 beds, 8 (25%) had 500–1,000 beds, 15 (46.9%) had
250–499, and 5 (15.6%) had <250. Twelve (37.5%) were
university or tertiary-care hospitals, and 20 (62.5%) were
general or secondary-care hospitals.
Quality Control Results 
Among participating laboratories, the overall concor-
dance of susceptibility to ampicillin, gentamicin, and
ciprofloxacin in the 6 E. coli control strains was 100%,
89%–100%, and 92%–100%, respectively. ESBL produc-
tion was detected by 85.2%–97% of the laboratories. The
participating laboratories used NCCLS-recommended pro-
cedures for ESBL detection (18).
In the few cases of disagreement between the expected
quality control results and the actual performance of indi-
vidual laboratories, individual cases were analyzed and
discussed with participants. Measures to improve laborato-
ry procedures were proposed when necessary, including the
dispatch of isolates to the Spanish E. coli reference labora-
tory (352 [4.9%] strains submitted during the study period).
Patient Data 
Data on 7,098 isolates of E. coli, corresponding to the
same number of patients, were reported, including 3,484
(49.1%) male patients, 3,581 (50.5%) female patients, and
33 of unknown sex. All isolates were collected from blood
except 9 from CSF. Of the total number of isolates, 309
(4.4%) were from children <14 years of age, 2,145
(30.2%) were from patients ≥15 and <64 years of age, and
4,644 (65.4%) were from patients >64 years of age. Atotal
of 3,339 (47.3%) isolates were implicated in nosocomial
infections (1,465 from internal medicine, 442 from sur-
gery, 309 from pediatrics, 290 from intensive care units, 81
from infectious diseases, 75 from obstetrics and gyneco-
logy, and 677 from other departments), and 3,735 (52.6%)
isolates were implicated in community-acquired infec-
tions; in 24 cases this information was missing.
Antimicrobial Susceptibility
The antimicrobial susceptibility of the E. coli isolates
studied is shown in Table 1. In the E. coli isolates, resist-
ance to ampicillin, cotrimoxazole, ciprofloxacin, gentam-
icin, and tobramycin was found at rates of 59.9%, 32.6%,
19.3%, 6.8%, and 5.3%, respectively. Of the 7,098 isolates
tested for cefotaxime, 234 isolates (3.3%) were nonsuscep-
tible, including 19 (0.3%) intermediate and 215 (3%)
resistant. ESBL producers totaled 204 (2.9% of all strains
tested for cefotaxime) isolates. Ceftazidime susceptibility
data were available for 5,960 isolates. Of these, 209 (3.5%)
were nonsusceptible, including 10 (0.2%) intermediate and
199 (3.3%) resistant. 
Among the 185 E. coli ESBL producers in which sus-
ceptibility data to both cefotaxime and ceftazidime were
reported, nonsusceptibility to cefotaxime according to
MIC data was found in 113 (61.1%) cases, while nonsus-
ceptibility to ceftazidime was reported in 68 cases
(36.8%). Resistance figures to other antimicrobial agents
were as follows: imipenem, 0% of 4,504 isolates tested;
amikacin, 0.3% of 4,484 isolates tested; and
amoxicillin/clavulanic acid, 6% intermediate and 4.5%
resistant of 3,023 isolates tested. 
The prevalence of antimicrobial resistance was higher
in male patients than in female patients (Table 2), particu-
larly for ciprofloxacin, gentamicin, and cotrimoxazole.
Nosocomial isolates were significantly more resistant to
ampicillin, ciprofloxacin, cotrimoxazole, gentamicin, and
cefotaxime than community-acquired isolates (Table 3).
Of the 204 ESBL producers, 66 (32.4%) were implicated
in community-onset infections. Resistance to ciprofloxacin
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>500 beds than in those from hospitals with <500 beds,
24.6% vs. 21.3% (p = 0.02, OR 1.2, 95% CI 1.02–1.42).
No statistical differences were found in the resistance fig-
ures to other antimicrobial agents according to hospital
size. In general, antimicrobial resistance did not vary in
relation to hospital departments; however, resistance to
gentamicin was more prevalent in intensive care units than
in internal medicine, 10.5% vs. 6.8% (p = 0.04, OR 1.57,
95% CI 1.02–2.40).
Isolates from children <14 years of age were signifi-
cantly more resistant to ampicillin than those from patients
>14 years of age, 63% vs. 57.4% (p = 0.047, OR 1.27, 95%
CI 1–1.62). In contrast, ciprofloxacin resistance was less
prevalent in children than in adults, 8.8% vs. 20% (p <
0.001, OR 0.38, 95% CI 0.25–0.58). In the other antimi-
crobial agents tested, no differences relating to patient age
were apparent. Among the 27 ciprofloxacin resistance iso-
lates from children, 3 (11.1%) were also ESBL producers. 
Resistance to cotrimoxazole, ciprofloxacin, and gen-
tamicin was more prevalent in ampicillin-resistant (46.7%,
27.7%, and 10.8%, respectively) strains than in ampicillin-
susceptible strains (9.9%, 8.5%, and 1.8%, respectively) (p
< 0.001). Also, E. coli ESBL-producing strains were sig-
nificantly more resistant to other non–β-lactam antimicro-
bial agents than nonproducing strains, as was the case for
ciprofloxacin (57.4% vs. 18.4%; p < 0.001), cotrimoxazole
(56.8% vs. 30.3%; p < 0.001), and gentamicin (22.5% vs.
6.5%; p < 0.001). Of the 1,372 ciprofloxacin-resistant iso-
lates, 113 (8.2%) were also ESBL producers. In contrast,
of 5,673 ciprofloxacin susceptible isolates, only 91 (1.6%)
were ESBL producers (p < 0.001, OR 5.59, 95% CI
4.21–7.42).
Of the 5,018 (70.7%) strains tested for simultaneous
susceptibility to ampicillin, ciprofloxacin, gentamicin, cot-
rimoxazole, cefotaxime and ceftazidime, multidrug resist-
ance was present in 863 (17.2%) isolates. The most
prevalent phenotypes included resistance to ampicillin,
cotrimoxazole, and ciprofloxacin, which was detected in
382 isolates (44.3% of multidrug-resistant strains and
7.6% of strains overall) and resistance to ampicillin, cotri-
moxazole, ciprofloxacin, and gentamicin, detected in 151
strains (17.5% of multidrug-resistant strains and 3% of
strains overall).
Trends in Antimicrobial Resistance
Ampicillin and cotrimoxazole resistance did not signif-
icantly vary over the study period, from 58.4% (2001) to
57.9% (2003) and from 32.9% (2001) to 31.9% (2003),
respectively (Figure 1). However, resistance to cipro-
floxacin increased from 17.2% in 2001 to 21.1% in 2003
(3.9% change) (p < 0.001, OR 1.29, 95% CI 1.11–1.50)
(Figure 2). 
The prevalence of ciprofloxacin resistance in communi-
ty-acquired isolates increased from 13.3% in 2001 to 19.3%
in 2003 (6% change) (p = 0.0002, OR 1.56, 95% CI
1.22–1.98), a higher increase than that observed for all
strains. Figures 2 and 3 show the evolution of community
quinolone and cotrimoxazole use compared with resistance
to ciprofloxacin and cotrimoxazole, respectively, in inva-
sive community-acquired E. coli infections. In the first case
(Figure 2), both parameters increased, but cotrimoxazole
use was strongly reduced from 1965 to 2003, while resist-
ance figures remained near 30% (2001–2003) (Figure 3). 
The global rates of invasive E. coli ESBL producers
increased from 1.6% (2001) to 4.1% (2003) (2.5% change)
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Community-acquired ESBL producers increased from
0.4% (2001) to 1.5% (2003) (1.1% change) (p < 0.001, OR
3.74, 95% CI 1.68–8.67). 
Regarding susceptibility to third-generation cephalo-
sporins, the number of strains nonsusceptible to cefo-
taxime (MIC >8 µg/mL) but susceptible to ceftazidime
(MIC <8 µg/mL), increased from 26.5% in 2001 to 39.8%
in 2003 (13.3% change) (p < 0.0001, OR 1.83, 95% CI
1.59–2.12). The prevalence of multidrug resistance among
isolates tested for ampicillin, ciprofloxacin, gentamicin,
cotrimoxazole, cefotaxime, and ceftazidime was 13.8% in
2001, 16.1% in 2002, and 20.6% in 2003 (p < 0.0001, OR
1.62, CI 95% 1.33–1.97) (Figure 1). 
Antimicrobial Use
Total β-lactam use decreased from 13.34 DDD/1,000
inhabitants/day in 1998 to 11.44 DDD/1,000
inhabitants/day in 2003 (14.5% change). Consumption of
broad-spectrum penicillins and cephalosporins decreased
from 6.02 to 4.52 DDD/1,000 inhabitants/day (24.9%
change) and from 2.65 to 2.20 DDD/1,000 inhabitants/day
(17% change), respectively. In contrast, the use of amoxi-
cillin/clavulanate (4.67 DDD/1,000 inhabitants/day in
1998 to 6.54 DDD/1,000 inhabitants/day in 2003) and
quinolones (1.96 DDD/1,000 inhabitants/day in 1998 to
2.69 DDD/1,000 inhabitants/day in 2003) increased by
40% and 37.2%, respectively. Ciprofloxacin use remained
stable; levofloxacin and moxifloxacin use increased. From
1998 to 2003, cotrimoxazole consumption was very low
and decreasing. However, when analyzed from 1985, cot-
rimoxazole use decreased by 89.4%, from 3.2 DDD/1,000
inhabitants/day to 0.34 DDD/1,000 inhabitants/day
(Figure 3).
Discussion
Epidemiologic surveillance of antimicrobial resistance
is indispensable for empirically treating infections, imple-
menting resistance control measures, and preventing the
spread of antimicrobial-resistant microorganisms (21). The
EARSS network, which includes >700 laboratories, is the
official European network of national surveillance sys-
tems. It aims to collect comparable and reliable antimicro-
bial resistance data, with susceptibility data provided by
each microbiology laboratory according to standard meth-
ods, mainly based on NCCLS rules. 
This European network has some important character-
istics as a surveillance system for resistance to antimicro-
bial agents (22). These characteristics include the
following: 1) aggregation of data by each individual coun-
try and overall European countries, 2) rapid analysis and
diffusion of data, 3) early detection systems for antimicro-
bial resistance in pathogens of clinical and public health
relevance, and 4) basic decision support for public health.
Use of the information generated by the primary clini-
cal laboratory has several disadvantages, namely, the pos-
sible variability in the antimicrobial agents assayed, the
study methods used, and the interpretative criteria
employed. In our experience, however, most laboratories
used NCCLS-recommended methods. Previous validation
of antimicrobial susceptibility results from 22 European
countries, including Spain, has been performed by EARSS
researchers (23). In addition, cross-validation of routine
data gathering and centralized surveys has been imple-
mented previously (24). 
In this study, E. coli ESBL producers were infrequent
(2.9%) but much higher than the 0.36% found in 1,918
European clinical blood isolates of E. coli isolated from
1997 to 1998 (7). One of the ESBL producer strains
included in the quality control was undetected by 15% of
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Figure l. Annual evolution of antimicrobial resistance in invasive
Escherichia coli isolated by Spanish laboratories participating in
European Antimicrobial Resistance Surveillance System, 2001–
2003.the laboratories; this potential misclassification could lead
to underestimates of the prevalence of ESBL isolates in
this study. When ceftazidime nonsusceptibility was used as
a surrogate marker for ESBL, 1.2% of 71,800 E. coli iso-
lated from blood in the United States were nonsusceptible
to ceftazidime (25).
In addition, 32.4% of ESBL producers were implicated
in community-acquired infections. Although no data about
possible previous healthcare contact of the persons infect-
ed with ESBLin the community were available, the spread
of these types of β-lactamases outside hospitals is a matter
of great concern. 
We found a significant increase in ESBL production in
recent years in Spain, which affected both total and com-
munity-acquired isolates. In addition, the increased preva-
lence of isolates showing nonsusceptibility to cefotaxime
but susceptibility to ceftazidime (26.5% in 2001 vs.
39.8% in 2003) suggests that ESBL cefotaximases were
increasing quickly, as described by other studies (12,13).
In 2003 the first report from the United States appeared; it
documented the isolation of E. coli isolates producing
CTX-M–like ESBL (9 strains from 5 U.S. states) (26).
The emergence of this ESBL-type has important implica-
tions for the detection of ESBL E. coli producers in clini-
cal and epidemiologic surveys and emphasizes the need
for ESBL screening to include both cefotaxime and cef-
tazidime.
Fluoroquinolone use has increased in many European
countries (11,17), with Spanish consumption increasing
from 1.96 DDD/1,000 inhabitants/day in 1998 to 2.69
DDD/1,000 inhabitants/day in 2003 (37.2%). In compari-
son with other European countries participating in EARSS
that provided susceptibility results for at least 750 E. coli
invasive isolates in 2003, ciprofloxacin resistance in Spain
(21.1%) was among the highest in Europe. This figure is
lower than that in Portugal (25.8%) and Italy (25.3%) but
higher than percentages in such countries as Germany
(15.2%), Belgium (11.6%), Greece (9.9%), Ireland (9.6%),
France (9.4%), and the Netherlands (6.8%).
Isolates from children had a relatively high prevalence
of ciprofloxacin resistance (8.8%), although ciprofloxacin
was not used by children. This resistance could be due to
the transmission of resistant isolates between adults and
children in families, daycare, or school settings and to the
use of fluoroquinolones in poultry populations (10).
In a recent survey of 494 U.S. hospitals, the prevalence
of ciprofloxacin resistance was 6%; it had increased in
40% of the participant hospitals (27). Also, among 286,187
isolates of E. coli from urinary tract infections in female
outpatients in the United States, ciprofloxacin was the only
agent studied that demonstrated a consistent stepwise
increase in resistance from 1995 (0.7%) to 2001 (2.5%)
(28). In our study, a significant increase in ciprofloxacin
resistance, principally in community-onset infections,
coincided with rising community quinolone use.
Association between fluoroquinolone use and quinolone-
resistant E. coli has been described recently (29). 
Cotrimoxazole resistance remained stable in this study,
≈30%, and similar to the 27% reported in urinary tract
infection isolates in 1993 in Spain (30), in spite of the great
reduction (89.4%) found in community cotrimoxazole use
in the last 18 years. A similar situation was described pre-
viously with sulfonamide resistance in the United
Kingdom (31). In areas with high resistance rates main-
tained over long periods of time, reduction in antimicrobial
pressure may have a slower effect, especially in the pres-
ence of multidrug resistance (32). This may be due to
genetic linkage between resistance mechanisms and, there-
fore, co-selection by using only 1 antimicrobial agent (31),
or to the reservoir of molecular resistance mechanisms in
species of commensal flora (33). 
Antimicrobial resistance, principally to ciprofloxacin
and gentamicin, varied between the sexes, with isolates
from male patients more resistant than those from female
patients. Similar trends have been described recently in the
United States (9) and the Netherlands (11). Nosocomial
isolates were also more resistant than community-acquired
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Figure 2. Evolution of community quinolone consumption and
prevalence of resistance to ciprofloxacin in invasive community-
acquired  Escherichia coli infections (European Antimicrobial
Resistance Surveillance System, Spain 2001–2003). DDD,
defined daily doses. 1, January–June; 2, July–December. 
Figure 3. Annual evolution of community cotrimoxazole consump-
tion and prevalence of resistance to cotrimoxazole in invasive
community-acquired  Escherichia coli infections, European
Antimicrobial Resistance Surveillance System, Spain, 2001–2003.
DDD, defined daily dose. ones, similar to findings from a recent study in South
Korea (34). In both cases, these data probably reflect the
tendency for male patients and hospitalized patients to
more frequently have complicated urinary tract infections,
the principal source of invasive E. coli, which may be
associated with more chronic pathologic conditions and
more antimicrobial treatments. Possibly the most impor-
tant determining factor in resistance is use of antimicrobial
agents, as described for ciprofloxacin (Figure 2) (29). 
In our study, multidrug resistance was frequent (17.2%)
and increased by 50% during the study period
(2001–2003). Multidrug resistance in the United States
among 38,835 urinary tract infection isolates was 7.1% in
2000 (9). Such multidrug resistance has important implica-
tions for the empiric therapy of infections caused by E. coli
and for the possible co-selection of antimicrobial resist-
ance mediated by multidrug resistance plasmids (35), as
described above. 
Because antimicrobial resistance patterns are continual-
ly evolving and E. coli invasive isolates undergo progres-
sive antimicrobial resistance, continuously updated data on
antimicrobial susceptibility profiles will continue to be
essential to ensure the provision of safe and effective
empiric therapies. Moreover, results obtained from these
surveillance systems must be used to implement preven-
tion programs and policy decisions to prevent emergence
and spread of antimicrobial resistance. 
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